Eli Lilly, Verge Partner to Identify and Test Potential ALS Therapies

Eli Lilly, Verge Partner to Identify and Test Potential ALS Therapies

299500

Eli Lilly, Verge Partner to Identify and Test Potential ALS Therapies

Verge Genomics and Eli Lilly have entered into a three-year collaboration to find and develop therapies for amyotrophic lateral sclerosis (ALS). Verge will focus on discovering and validating potential new therapeutic targets, while Lilly will select up to four candidates to advance through clinical testing with a goal of bringing them into commercial use. “Lilly’s focus and leadership in neurology matches well with Verge’s ability to identify high-potential targets for devastating neurological diseases,” Alice Zhang, PhD, Verge’s…

You must be logged in to read/download the full post.